For an adult with arthritis, which medication—celecoxib (Celebrex) or hydroxychloroquine (Plaquenil)—is more effective?

Celecoxib (Celebrex) is more effective than hydroxychloroquine (Plaquenil) for arthritis symptom relief, but the choice depends critically on the type of arthritis.

Type of Arthritis Determines the Answer

For Osteoarthritis (OA):

• Celecoxib is clearly superior 1. Celecoxib demonstrated significant reduction in joint pain and improvement in WOMAC scores (composite of pain, stiffness, and functional measures) at doses of 100-200 mg twice daily 1. Pain relief begins within 24-48 hours 1.
• Hydroxychloroquine is ineffective for OA 2, 3. The highest quality randomized controlled trial showed hydroxychloroquine was no more effective than placebo for hand OA pain relief (mean pain scores: 5.66 vs 5.49 on 0-10 scale, p=0.57) 2. A subsequent trial in erosive OA confirmed these findings at 52 weeks 3.

For Rheumatoid Arthritis (RA):

• Celecoxib provides superior symptom relief 1. It demonstrated significant reduction in joint tenderness/pain and swelling using ACR20 criteria at 100-200 mg twice daily 1.
• However, hydroxychloroquine is the preferred DMARD for disease modification 4, 5, 6. Current ACR guidelines strongly recommend starting conventional synthetic DMARDs (with methotrexate preferred, but hydroxychloroquine as an option) for disease-modifying effects 4, 5. Hydroxychloroquine shows moderate clinical efficacy in RA 7, 8 and provides crucial cardiovascular protection 9, 10.

Critical Distinction: Symptom Relief vs Disease Modification

Celecoxib is an NSAID that provides:

• Rapid pain and inflammation relief (within 24-48 hours) 1
• No disease-modifying properties
• Significant GI risks (32,000 hospitalizations and 3,200 deaths annually from NSAID-related GI bleeding in the US) 11
• Cardiovascular risks, particularly with prolonged use 12

Hydroxychloroquine is a DMARD that provides:

• Slower onset of action (weeks to months)
• Disease-modifying effects in inflammatory arthritis 13, 7
• Cardiovascular protection in RA and SLE 9, 10
• Excellent safety profile with minimal serious adverse effects 2, 3

Practical Treatment Algorithm

If the patient has OA:

1. Use celecoxib 100-200 mg twice daily for symptom control 1
2. Do NOT use hydroxychloroquine—it is ineffective 2, 3
3. Consider GI prophylaxis if risk factors present (age >65, prior ulcer, anticoagulant use) 11, 12

If the patient has RA:

1. Start hydroxychloroquine (or methotrexate) as the foundational DMARD 4, 5, 6
2. Add celecoxib SHORT-TERM (<3 months) for symptom bridging while waiting for DMARD onset 5
3. Taper and discontinue celecoxib once DMARD achieves effect 5
4. Avoid chronic NSAID use due to cumulative GI and cardiovascular risks 11, 12

Common Pitfalls to Avoid

• Do not use hydroxychloroquine for OA—multiple high-quality trials prove it's ineffective 2, 3
• Do not rely on celecoxib alone for RA—you'll control symptoms but allow progressive joint damage 4, 5
• Do not use celecoxib chronically without GI risk assessment—the one-year risk of serious GI bleeding ranges from 1 in 2,100 (age <45) to 1 in 353 (age >75) 11
• Do not combine celecoxib with aspirin without PPI prophylaxis—this increases GI bleeding risk >10-fold 12

Dosing Specifics

Celecoxib for OA/RA: 100-200 mg twice daily (200 mg twice daily provides no additional benefit over 100 mg twice daily for most patients) 1

Hydroxychloroquine for RA: 200-400 mg daily 13, 8